Medtronic plc
Medtronic plc designs, manufactures, and sells medical technologies used to diagnose, treat, and manage chronic and acute conditions across the body. Its portfolio spans cardiac, vascular, neurological, spinal, surgical, respiratory, monitoring, and diabetes therapies, sold to hospitals, physicians, and care systems in more than 150 countries.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueDevices for cardiac rhythm disorders, vascular disease, and structural heart interventions.
Surgical, endoscopy, advanced energy, and patient monitoring products used across care settings.
Spinal, brain, pain, and neurological therapies including implants and related systems.
Insulin pumps, CGM-related offerings, and automated insulin delivery solutions.
Respiratory, airway, and other smaller product lines not captured in the core categories.
Customers
Medtronic sells primarily to healthcare systems, hospitals, ambulatory surgical centers, and alternate care facilities, with purchasing often influenced by physicians, clinicians, materials managers, GPOs, and IDNs. Demand is driven by clinical outcomes, reliability, reimbursement, and the ability to support complex procedures and chronic disease management. The company also serves patients indirectly through provider adoption of its therapies and devices.
Buy implantable, surgical, cardiovascular, and monitoring devices for procedures and ongoing care.
Influence product selection by specialty and use Medtronic therapies in procedures and treatment pathways.
Purchase surgical and monitoring products for outpatient procedures where efficiency matters.
Negotiate contracts and pricing on behalf of member facilities, shaping access and reimbursement economics.
Use respiratory, monitoring, and selected therapy products in home care and long-term care settings.
Strategy
Medtronic is focused on innovation-led growth, using its pipeline and recent launches to expand in large end markets. It is also emphasizing better patient and provider experiences, while balancing capital allocation between R&D, dividends, share repurchases, debt service, and acquisitions.
New therapies and devices are central to growth in fast-changing medical markets.
Management sees international markets as under-penetrated and a major growth opportunity.
Device quality, reliability, and easier deployment support pricing power and reduce recall risk.
Geography
Q1/2026Medtronic is headquartered in Galway, Ireland, and operates globally across more than 150 countries. Management identifies the U.S., Western Europe, China, and Japan as its four largest markets, while international markets are described as under-penetrated and a growth opportunity. The business is exposed to local reimbursement, tender pricing, regulation, and currency movements in each region.
Share of the revenue the company reports by geography.
Risks
Medtronic faces intense competition, reimbursement pressure, and product-quality risk in a market where clinical performance and safety directly affect demand. Its global footprint also exposes it to regulatory delays, trade policy changes, currency swings, cybersecurity threats, and litigation tied to implanted or high-risk devices.
- Product quality, recalls, and liabilityImpact: CriticalLikelihood: Medium
Implantable and life-supporting devices can cause patient harm if they fail, leading to recalls, lawsuits, and reputational damage.
Exposure: Implantable and intensive-care products
- Reimbursement and pricing pressureImpact: HighLikelihood: High
Managed care, provider consolidation, and national/provincial tender pricing can lower margins and slow adoption.
Exposure - Intense competition and product substitutionImpact: HighLikelihood: Medium
The company competes across many device categories against large and specialized rivals, plus alternative therapies like GLP-1s.
Exposure - Cybersecurity and data privacyImpact: HighLikelihood: Medium
Global operations and connected systems increase exposure to breaches, regulatory action, and litigation.
Exposure - Tariffs, trade policy, and FX volatilityImpact: MediumLikelihood: Medium
A global supply chain and international sales base make costs and reported results sensitive to macro shocks.
Exposure
Accounting
Judgemental itemsFour reporting units are tested using projected cash flows, discount rates, and market multiples; small assumption changes can materially affect carrying values.
Impact: Could lead to material non-cash charges if growth or margins weaken
Definite-lived intangibles depend on future product performance and regulatory outcomes.
Impact: Potential write-downs if product lines underperform
Some revenue is generated from inventory maintained at hospitals, which can affect when sales are recognized.
Impact: Quarterly revenue comparability and working capital
Management adjusts for non-GAAP items when presenting tax rate and free cash flow, affecting comparability.
Impact: Investor interpretation of earnings quality and cash generation
Similar listed companies
Publicly listed companies with a comparable business focus.
Medline Inc.
MDLN · Surgical & Medical Instruments & Apparatus
Dynatronics Corp
DYNTQ · Surgical & Medical Instruments & Apparatus
Dynatronics Corp designs, manufactures, and sells restorative medical products used in physical therapy, rehabilitation, orthopedics, pain management, and athletic training.
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
Stryker Corporation
SYK · Surgical & Medical Instruments & Apparatus
Merit Medical Systems, Inc
MMSI · Surgical & Medical Instruments & Apparatus
Merit Medical Systems designs, manufactures, and markets proprietary medical devices used in interventional, diagnostic, and therapeutic procedures.
Glucotrack, Inc.
GCTK · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026